Research


Clinical Trials Unit


Research Overview

Center for Medical
Mycology

Clinical Trials Unit

Murdough Family
Center for Psoriasis

Skin Diseases
Research Center

Skin Study Center

Training Grant











Clinical Trials Unit Staff:  Danielle Moul MD, Kimberly Phillips RN, Zsa Zsa Hann, MaryAnn Bucholtz RN, Shannon Routhouska MD, and Neil J. Korman MD PhDClinical studies are ongoing to evaluate the efficacy of new therapeutic agents for variety of indications. The staff are experienced in topical, systemic and novel biologic therapeutics. They coordinate trials across multiple locations, including the NIH-funded General Clinical Research Center and the Ireland Cancer Center Infusion Unit. The Clinical Trials Unit (CTU) maintains a professional infrastructure for testing new agents and protocols for patients with skin diseases. The dermatology CTU provides a resource for industry and government for skilled assessment of skin disease. The Department has cultivated a very large pool of patients, both from within the institution and from a large referral base, who are regularly recruited into clinical trials, effecting rapid enrollment. The CTU is actively involved in study design, all phases of clinical testing, and the FDA approval process of investigational new drugs.

The Clinical Trials Unit of the Department of Dermatology provides patients with the opportunity to participate in studies of the newest medications that are being evaluated as potential therapies. Past projects include trials in psoriasis, eczema, skin lymphoma, melanoma, shingles, pemphigus, bullous pemphigoid, alopecia, acne, warts, fungal infections, onychomycosis, tinea pedis/cruris/versicolor, herpes zoster, genital warts, postherpic neuralgia, Kaposi's sarcoma, graft vs. host disease, urticaria, and photoaging. All patients seen in our practice are eligible to enroll in such studies which are funded by pharmaceutical, private, or governmental sources.

 

Current Clinical Trials
  • Adult open label study to evaluate the effectiveness and safety of Enbrel in the treatment of adults (ages 18 and older) with moderate to severe plaqe psoriasis
  • Adults (ages 18 and older) placebo controlled trial with a topical agent for patients wiht mild to severe psoriasis
  • The treatment of moderate to severe atopic dermatitis with Raptiva
  • The treatment of psoriasis with IL-12 antibody
  • The treatment of severe lichen planus with Enbrel
  • The treatment of moderate to severe cutaneous lupus erythematosus with a new monoclonal antibody
  • Treatment of cutaneous T cell lymphoma with fully human CD4
  • Effects of green tea cream on cutaneous vasodilatation
  • Treatment of CD30+ lymphoproliferative disorders (lympomatoid papulosis and CD30+ larc cell lymphoma)
  • Phase 1 clinical trial using topical silicon phthalocyanine (Pc4) photodynamic therapy (PDT) for the treatment of pre-malignant and malignant skin conditions (CTCL, AK, BCC, SCC)
  • 06 Benzylguanine-potentiated topical BCNU for CTCL
  • Photpheresis for treatment of early stage cutaneous T cell lymphoma
  • Mechanisms of excimer laser UV therapy in psoriasis

For more information regarding our clinical trials, please call 216-844-7394.

Back to top

 

 



For questions or comments, contact Webmaster
Copyright 2004, Case Western Reserve University, Department of Dermatology. All Rights Reserved.
All materials are provided by the Department of Dermatology and are the property of the Department.
No material from this site may be copied, reproduced, republished, uploaded, posted, transmitted, or distributed in any way.

Downtown Cleveland